Clear All
12611 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
70710-1744-03 70710-1744 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 3, 2025 In Use
67184-0533-01 67184-0533 Imatinib mesylate Imatinib mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 21, 2022 In Use
63629-2068-01 63629-2068 IMATINIB MESYLATE IMATINIB MESYLATE 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb 8, 2019 Jun 30, 2023 No Longer Used
59651-0547-30 59651-0547 DASATINIB DASATINIB 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Apr 22, 2025 In Use
72606-0556-01 72606-0556 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Nov 6, 2019 In Use
54868-5427-02 54868-5427 Imatinib Mesylate Gleevec Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Nov 9, 2005 Jun 30, 2013 No Longer Used
60505-3801-07 60505-3801 Nilotinib Nilotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Mar 25, 2025 In Use
60505-2901-00 60505-2901 Imatinib Mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 5, 2016 In Use
72205-0239-64 72205-0239 Nilotinib Nilotinib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Nov 20, 2025 In Use
00832-0532-09 00832-0532 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 17, 2024 Jan 31, 2027 In Use
60505-2900-00 60505-2900 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 5, 2016 In Use
66993-0236-30 66993-0236 Dasatinib Dasatinib 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 3, 2024 In Use
69097-0576-08 69097-0576 nilotinib NILCEYA 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 30, 2025 In Use
69097-0032-91 69097-0032 Nilotinib Nilotinib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 18, 2025 In Use
66993-0237-30 66993-0237 Dasatinib Dasatinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sep 3, 2024 In Use
70709-0191-12 70709-0191 Nilotinib CAVHANZA 60.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jun 30, 2026 In Use
43598-0055-04 43598-0055 Nilotinib Nilotinib 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Nov 19, 2025 In Use
61755-0054-01 61755-0054 Linvoseltamab-gcpt LYNOZYFIC 5.0 mg/2.5mL Immunotherapy Monoclonal Antibody BCMA, CD3 Intravenous Jul 2, 2025 In Use
00069-2522-02 00069-2522 Elranatamab-bcmm Elrexfio 44.0 mg/1.1mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Aug 15, 2023 In Use
63539-0252-02 63539-0252 Elranatamab-bcmm Elrexfio 44.0 mg/1.1mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Aug 15, 2023 In Use
00069-4494-02 00069-4494 Elranatamab-bcmm Elrexfio 76.0 mg/1.9mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Aug 15, 2023 In Use
57894-0449-01 57894-0449 Teclistamab-cqyv TECVAYLI 10.0 mg/mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Oct 25, 2022 In Use
57894-0450-01 57894-0450 Teclistamab-cqyv TECVAYLI 90.0 mg/mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Oct 25, 2022 In Use
61755-0056-01 61755-0056 Linvoseltamab-gcpt LYNOZYFIC 200.0 mg/10mL Immunotherapy Monoclonal Antibody BCMA, CD3 Intravenous Jul 2, 2025 In Use
00173-0896-01 00173-0896 Belantamab Blenrep 50.0 mg/mL Immunotherapy Drug Antibody Conjugate BCMA Intravenous Aug 5, 2020 Jun 30, 2024 No Longer Used

Found 12611 results — Export these results